| |
Integrated digital solutions are essential to the success of modern trials. Discover how IQVIA led a unified delivery team to streamline operations and implement a purpose-built, integrated IRT and Complete Consent solution. Download the case study! 
|
|
| By Fraiser Kansteiner Under a mutual agreement with Novo Nordisk's board of directors, Lars Fruergaard Jørgensen is stepping down from the chief executive post he’s held for the past eight years. Novo didn’t mince words about the rationale behind the decision, pointing to “recent market challenges” and the precipitous decline of the company’s share price “since mid-2024.” |
|
|
|
By Nick Paul Taylor Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to BioNTech, Merck & Co. and Summit Therapeutics in a scorching-hot area of immuno-oncology. |
By Eric Sagonowsky President Donald Trump's recent Executive Order on drug prices applies to "all brand products across all markets that do not currently have generic or biosimilar competition," the HHS said in a Tuesday press release. |
By Zoey Becker FDA Commissioner Marty Makary, M.D., and CBER head Vinay Prasad, M.D., detailed their new approach to COVID vaccines in a Tuesday update. The agency leaders say they're pursuing an "evidence-based approach to COVID-19 vaccination." |
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness. 
|
|
By Gabrielle Masson Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine and laying off an undisclosed number of staffers. |
By Conor Hale The drugmaker Regeneron has won a bankruptcy auction for 23andMe and its DNA database gathered from some 15 million customers. |
By Nick Paul Taylor Analysts have given muted reception to Boehringer Ingelheim’s long-awaited phase 3 lung disease data, calling nerandomilast “a step forward but not game-changing.” |
By Fraiser Kansteiner Eli Lilly is jockeying for a tax break in Texas as it weighs whether to build a $5.9 billion API facility in Houston, according to a state filing. When reached for comment, Lilly did not go into details about the Texas proposal but confirmed it’s related to the broader $27 billion U.S. manufacturing investment the company unveiled in late February. |
By Darren Incorvaia A team of scientists has harnessed CRISPR technology to identify a protein that helps cancers spread to bone tissue, opening the door for potential therapies to prevent the common and painful disease progression. |
By Andrea Park Fresh off taking the top spot in an annual survey of how patient groups around the world view major drugmakers, ViiV Healthcare has clinched the No. 1 slot in a U.S.-specific version of the survey, too. |
Fierce podcasts Don’t miss an episode |
| Despite all the AI hype, most healthcare organizations are stuck in pilot mode. This week on "Podnosis," Fierce Healthcare Executive Editor Heather Landi explores why so few projects scale and what moving from promise to progress will take. |
|
|---|
|
|
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more. 
|
|
Whitepaper Explore how NLP and generative AI, including models like ChatGPT, are transforming precision medicine and life sciences. Sponsored by: IMO Health |
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
